特拉唑嗪联合坦索罗辛治疗前列腺增生患者的临床效果及对血清PSA、TNF-α水平的影响

doi:10.3969/j.issn.1671-7171.2021.06.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1115 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨特拉唑嗪联合坦索罗辛对前列腺增生患者的临床效果及对血清PSA、TNF-α水平的影响。【方法】回顾性分析2017年12月至2019年4月本院收治的102例前列腺增生患者的临床资料,根据治疗方案的不同将其分为观察组(n=50)和对照组(n=52),对照组患者采用特拉唑嗪进行治疗,观察组在对照组的基础上联合坦索罗辛进行治疗。比较两组患者治疗后临床效果,比较两组患者血清前列腺特异抗原(PSA)、肿瘤坏死因子-α(TNF-α)水平,记录患者治疗后最大尿流量、残余尿量以及国际前列腺症状评分(IPSS)。【结果】观察组患者治疗后的总有效率为92.0%(46/50),明显高于对照组的86.5%(45/52),差异有统计学意义(χ²=2.8319,P=0.004<0.05)。治疗后,观察组患者血清TNF-α、PSA水平明显低于对照组,两组比较差异有统计学意义(P<0.05);观察组患者治疗后最大尿流量、IPSS评分显著高于对照组,残余尿量显著低于对照组,两组比较差异有统计学意义(P<0.05)。【结论】特拉唑嗪联合坦索罗辛治疗能够有效改善前列腺增生患者最大尿流量以及残留尿量,降低患者PSA水平,提高抗炎免疫作用,值得在临床治疗中推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	徐娟
	李小雪

关键词 ：前列腺增生/药物疗法, 肾上腺素能α拮抗剂/治疗应用, 前列腺特异抗原/血液, 炎症

Abstract：【Objective】To investigate the clinical effect of terazosin combined with tamsulosin on patients with benign prostatic hyperplasia and its effect on the level of the impact of serum PSA and TNF-α. 【Methods】 The clinical data of 102 patients with benign prostatic hyperplasia in our hospital from December 2017 to April 2019 were retrospectively analyzed. According to different treatment schemes, they were divided into observation group (n=50) and control group (n=52). The control group was treated with terazosin, and the observation group was treated with tamsulosin on the basis of the control group. The clinical effect, serum prostate specific antigen (PSA) and tumor necrosis factor-α (TNF)-α were compared between the two groups. The maximum urine flow, residual urine volume and International Prostate Symptom Score (IPSS) were recorded. 【Results】The total effective rate of the observation group was 92.0% (46/50), significantly higher than 86.5% (45/52) of the control group, the difference was statistically significant(χ²=2.8319,P=0.004<0.05).After treatment, the level of serum TNF- αand PSA of the observation group was significantly higher than that of the control group, there was significant difference between the two groups (P<0.05). After treatment, the maximum urine flow and IPSS score of the observation group were significantly higher than those of the control group, and the residual urine volume of the observation group was significantly lower than that of the control group (P<0.05).【Conclusion】 Terazosin combined with tamsulosin can effectively improve the maximum urine flow and residual urine volume of patients with benign prostatic hyperplasia, reduce the level of PSA, and improve the anti-inflammatory immune effect, which is worthy of clinical application.

Key words： Prostatic Hyperplasia/DT Adrenergic alpha-Antagonists/TU Prostate-Specific Antigen/BL Inflammation

收稿日期: 2019-06-06

中图分类号:

R697.32

引用本文:

徐娟, 李小雪. 特拉唑嗪联合坦索罗辛治疗前列腺增生患者的临床效果及对血清PSA、TNF-α水平的影响[J]. 医学临床研究, 2021, 38(6): 873-875.
XU Juan, LI Xiao-xue. Clinical Effect of Terazosin Combined with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia and its Impact of the Level on Serum PSA and TNF- α. JOURNAL OF CLINICAL RESEARCH, 2021, 38(6): 873-875.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.06.019 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I6/873